Finoriq research workspace
MADRIGAL PHARMACEUTICALS, INC. (MDGL) Institutional Holdings & 13F Ownership
MADRIGAL PHARMACEUTICALS, INC. offers Rezdiffra, a liver-directed thyroid hormone receptor. Review MDGL institutional holders, 13F ownership, and position changes on Finoriq.
Company Snapshot
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.
- Company
- MADRIGAL PHARMACEUTICALS, INC. (MDGL)
- Ticker
- MDGL
- Market Cap
- $12.4B
- Latest Price
- $536.86
- Industry
- Biotech & Pharma
MADRIGAL PHARMACEUTICALS, INC. (MDGL) Top Institutional Holders
Top current 13F holders indexed for MADRIGAL PHARMACEUTICALS, INC. (MDGL). Latest period 2026-03-31.
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.